Posts

Global Alopecia Treatment Market

Global Seborrhea Market

/in /by

Global Seborrhea Drugs Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025

With the slowdown in world economic growth, the Seborrhea Drugs industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Seborrhea Drugs market size to maintain the average annual growth rate of XXX from XXX million $ in 2014 to XXX million $ in 2018, Stratagem Market Insights analysts believe that in the next few years, Seborrhea Drugs market size will be further expanded, we expect that by 2023, The market size of the Seborrhea Drugs will reach XXX million $.

This Report covers the manufacturers’ data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.

Besides, the report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

Section 1: Free——Definition

Section (2 3): 1200 USD——Manufacturer Detail

Aclaris Therapeutics Inc
Amorepacific Corp
Biomar Microbial Technologies
EpiPharm AG
Vyome Biosciences Pvt Ltd

Section 4: 900 USD——Region Segmentation
North America Country (United States, Canada)
South America
Asia Country (China, Japan, India, Korea)
Europe Country (Germany, UK, France, Italy)
Other Country (Middle East, Africa, GCC)

Section (5 6 7): 500 USD——

Product Type Segmentation
Artemether
Hydrogen Peroxide
Ketoconazole
Industry Segmentation
Hospital
Clinic
Channel (Direct Sales, Distributor) Segmentation

Section 8: 400 USD——Trend (2018-2023)

Section 9: 300 USD——Product Type Detail

Section 10: 700 USD——Downstream Consumer

Section 11: 200 USD——Cost Structure

Section 12: 500 USD——Conclusion

Global Seborrhea Drugs Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025

Source

Recent Posts

Global Alopecia Treatment Market

Global Seborrhea Market

/in /by

Global Seborrhea Drugs Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025

With the slowdown in world economic growth, the Seborrhea Drugs industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Seborrhea Drugs market size to maintain the average annual growth rate of XXX from XXX million $ in 2014 to XXX million $ in 2018, Stratagem Market Insights analysts believe that in the next few years, Seborrhea Drugs market size will be further expanded, we expect that by 2023, The market size of the Seborrhea Drugs will reach XXX million $.

This Report covers the manufacturers’ data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.

Besides, the report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

Section 1: Free——Definition

Section (2 3): 1200 USD——Manufacturer Detail

Aclaris Therapeutics Inc
Amorepacific Corp
Biomar Microbial Technologies
EpiPharm AG
Vyome Biosciences Pvt Ltd

Section 4: 900 USD——Region Segmentation
North America Country (United States, Canada)
South America
Asia Country (China, Japan, India, Korea)
Europe Country (Germany, UK, France, Italy)
Other Country (Middle East, Africa, GCC)

Section (5 6 7): 500 USD——

Product Type Segmentation
Artemether
Hydrogen Peroxide
Ketoconazole
Industry Segmentation
Hospital
Clinic
Channel (Direct Sales, Distributor) Segmentation

Section 8: 400 USD——Trend (2018-2023)

Section 9: 300 USD——Product Type Detail

Section 10: 700 USD——Downstream Consumer

Section 11: 200 USD——Cost Structure

Section 12: 500 USD——Conclusion

Global Seborrhea Drugs Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025

Source

Recent Posts

Hair Transplant Before and After Photos

Thinning Hair and Its Treatment

/in /by

Silicon Valley Hair Institute, the Bay Area Leader in Hair Transplantation, Announces New Post on Thinning Hair and Its Treatment

Silicon Valley Hair Institute, a best-in-class hair transplant clinic in the Bay Area is proud to announce a new post about the reasons for hair loss. The post advocates that a client speak to a top doctor about thinning hair and discover the underlying causes.

“How one approaches hair loss is all about how a client feels about the change. If hair loss is a hit to someone’s confidence, then we are here to help,” explained Dr. Miguel Canales, hair loss surgeon for SVHI. “My experience as a leading hair loss specialist in the Bay Area has led to the belief that each person can benefit from the right solution.”

Interested persons can review the new post by Silicon Valley Hair Institute https://siliconvalleyhairinstitute.com/suffering-from-thinning-hair-we-can-give-you-a-free-plan-of-action/. Patients concerned about hair loss can find information from a world-class Bay Area doctor for thinning hair.

Dr Miguel Canales helps men and women find solutions for different types of hair loss. Thinning hair can occur for various reasons such as genetics, a traumatic event, or simply the ageing process. It occurs in both men and women.

The right kind of therapy or surgery could bring back a youthful, full head of hair. Bay Area residents considering options for hair loss can schedule a no-obligation virtual consultation. To review the online hair loss consultation page, go to https://siliconvalleyhairinstitute.com/virtual/.

ABOUT SILICON VALLEY HAIR INSTITUTE

The Silicon Valley Hair Institute, under the leadership of top-rated California hair transplant surgeon Miguel Canales MD, offers professional San Francisco Bay Area hair restoration services.

Dr Canales provides the full range of advanced hair transplant and hair restoration procedures for Bay Area residents, from San Francisco to Palo Alto to San Jose. Treatments include; robotic hair transplants, FUE/FUT surgery, and micro-pigmentation. Persons searching for a hair transplant specialist with top reviews for successful results can contact this Bay Area hair transplant centre. The clinic provides both San Jose FUE transplant and San Francisco FUE transplant services. Dr. Canales also performs hair transplants for women and eyebrow restoration. The clinic is one of a few using the ARTAS robot for hair transplant surgery.

Silicon Valley Hair Institute, the Bay Area Leader in Hair Transplantation, Announces New Post on Thinning Hair and Its Treatment

Source

Recent Posts

Flourish to Combat Female Hair Loss

Flourish to Combat Female Hair Loss

/in /by

Virtue Labs Introduces Flourish to Combat Female Hair Loss

Virtue Labs, makers of the multi-award-winning biotech hair care brand Virtue®, announced today the launch of their new Flourish® product line specifically to target female hair loss and provide thicker, fuller, and healthier hair for all.

While traditionally considered a male problem, half of all women will suffer from hair loss in their lifetime, and 40% by the time they are 40 according to the American Academy of Dermatology.

In fact, there are an estimated 30 million women in the United States suffering from hair loss, and the numbers continue to accelerate. To address this problem, Virtue took a holistic approach in creating this new line by focusing on scalp fertility and, also importantly, on hair fiber survival, with each product in the line powered by their exclusive, groundbreaking keratin protein complex Alpha Keratin 60ku CLINICAL®.

As the scalp is the starting point for hair growth, Virtue Flourish starts there too. Flourish products create a fertile environment for hair to grow by nourishing the microbiome, clearing the follicles, and strengthening the moisture barrier. Because new hair can only survive if it is nurtured and cared for, the Alpha Keratin 60ku CLINICAL nourishes new fragile hair as it emerges, increasing the strength and thickness of each new fiber.

Independent clinical testing showed that after only five uses, Virtue Flourish with Alpha Keratin 60ku CLINICAL increased the thickness of individual hair strands by 22% and reduced hair breakage by 26%, thereby giving new hairs a better chance at survival.

“As a biotech brand born from regenerative medicine, Virtue has always gone where our technology has led us, and that is certainly true with Flourish.

After launching our initial Virtue hair care line, we kept hearing from customers that their hair was growing faster or that they thought they could see new growth. That sent us on a three-year journey of discovery to see what our technology could do if we partnered it with other ingredients specifically to address this crucial problem,” said Melisse Shaban, Founder & CEO of Virtue Labs. “Hair loss is a silent epidemic that women are facing alone. With this launch, we aim to provide truly efficacious products and to shatter the stigma of women’s hair loss with open conversation around this important topic.”

Virtue’s Flourish line features six products that can be purchased individually or within two three-step regimens. The Flourish Nightly Intensive Hair Growth Treatment Regimen ($134) is a three-month regimen for moderate to severe hair thinning and contains Minoxidil, the only single ingredient FDA-approved to help regrow hair in women. The Flourish Nightly Intensive Hair Rejuvenation Treatment Regimen ($134) is a 100% drug-free alternative that features Virtue’s new Density Booster to serve mild to moderate hair thinning and those seeking a more natural approach. The Flourish lineup includes:

  • Flourish Shampoo for Thinning Hair ($42): A gentle, stimulating shampoo that delicately removes scalp buildup, cleanses the hair shaft, and clears debris from follicle openings, creating an environment for healthy growth.
  • Flourish Conditioner for Thinning Hair ($44): A lightweight conditioner that serves as a hair strengthener, hydrator, and detangler all in one. Specifically developed for fine, fragile strands, it nourishes and thickens each hair without weighing it down.
  • Flourish Density Booster ($48): A potent, botanical-based, drug-free nutrient infusion for the scalp, the Density Booster works while you sleep to fuel fatigued follicles and nurture new, fragile hairs so they thrive. For those seeking a more natural solution.
  • Flourish Volumizing Styler ($42): The all-you-need styler for fine, fragile hair, this airy, lightweight formula provides instant body, bounce, and hold, creating the illusion of density even in the thinnest parts.
  • Minoxidil 5% ($28): Used by millions, this is the only single ingredient FDA approved to help regrow hair in women. The nightly application works while you sleep to reactivate the hair follicles and stimulate regrowth.
  • Flourish x Manta Brush ($32): Virtue partnered with U.K. based Manta to offer this uniquely designed brush created specifically for fragile hair. The revolutionary Manta brush bends and molds to the shape of your hand and scalp, creating less tension on each strand. Its flexible bristles glide responsively through the hair, minimizing breakage and restoring a youthful, silky shine.

Virtue Flourish products have been tested through an independent lab on real women under real conditions, and 97% said their scalp feels healthier, 90% said they had more volume and 90% said they saw new growth*.

“Traditionally, hair loss products have been difficult to use, and often harsh on the hair, so women give up before seeing results. Virtue Flourish begins immediately to improve the health and appearance of her existing hair so that she loves the way she looks while she’s growing more,” Shaban said. “We’re excited to present this innovation to women in their search for solutions to their hair loss or thinning.”

Virtue Flourish is available for purchase on virtueflourish.com and will be available in select Bluemercury stores and on Dermstore.com starting in April 2021.

* Consumer perception results after 6 months of Virtue Flourish® Regimen use. Hair growth was seen to be healthier.

+++

About Virtue Labs:

Virtue Labs manufactures and markets innovative, technology-based solutions for the health of hair that provide visible, transformational results. Its proprietary, patented hero ingredient, Alpha Keratin 60ku®, is keratin in its purest, native form – whole, unbroken and fully functional. It is the only fully functional, human-identical keratin protein on the market today, and it is found in each of the company’s Virtue® haircare products. Virtue Labs is based in Raleigh, NC, with a technology manufacturing facility in Winston-Salem, NC. For more information please visit: www.virtuelabs.com.

Virtue Labs Introduces Flourish to Combat Female Hair Loss

Source

Recent Posts

HairMax Welcomes Mary Brunetti as Brand Ambassador

HairMax Welcomes Mary Brunetti as Brand Ambassador

/in /by

HairMax Welcomes Mary Brunetti as Brand Ambassador to Provide Expert Guidance on Styling and Managing Multiple Causes of Thinning Hair Including Covid-19 Hair Loss

Mary is known as much for her celebrity clientele as she is for training world-class hairstylists. For nearly 20 years, Mary has implemented her unique training program at the Sally Hershberger salon in New York City, where she is the Director of Education.

Brunetti has been called upon to style the hair for many celebrities including, Bette Midler, Mariah Carey, Mariska Hargitay, Debra Messing, Eva Longoria, Carrie Underwood, Jane Krakowski, Brooke Shields, and Giada De Laurentiis, to name a few. Mary has styled hair backstage at Fashion Week for world-renowned designers such as Donna Karan, Nicole Miller, Naeem Kahn and Vivienne Westwood.

In addition, Brunetti’s work has been published in Vogue, Elle, Vanity Fair, New York magazine, Town & Country, Modern Bride, People, Mademoiselle as well as all the leading industry trade magazines including Modern Salon, American Salon and LaunchPad.

Mary maintains a clientele in her own Mary Brunetti Salon in the resort area of the Hamptons, N.Y., and continues to consult with top salons around the country on how to implement her tried and true training program.

Mary stated: “2020 brought many unexpected upheavals to the salon industry. Once we opened back up many of my clients began approaching me with their hair loss concerns, so I began looking into options.” Mary further stated, “In my research, I learned about the seven clinical studies that HairMax conducted on laser energy for hair growth, resulting in eight FDA clearances. I was wowed by science and the ongoing development of innovative technology for hair growth and hair wellness. I love the fact that as a Brand Ambassador for HairMax, I will be part of the solution that addresses a desperate situation for so many suffering from hair loss.”

“I only recommend products that I try myself, so I began using the LaserBand 82 hair growth device and saw the results. When it comes to hair growth and wellness, nothing compares to HairMax,” States Mary.

Francesca Dubsky, Director of Marketing stated: “There has been a significant uprise in reports of hair loss post-Covid-19, typically appearing 2-3 months after diagnosis. We have seen an increase in inquiries for information as to how to recognize and treat this occurrence. Mary joining us as Brand Ambassador will help educate people on how to deal with their Covid-19 related hair loss, as well as treatments for hereditary hair loss and how HairMax products can help them regrow and revitalize their hair.”

About HairMax:

Based in Boca Raton, Lexington Int’l is the pioneer and global leader in laser hair growth technology. HairMax Laser Devices are the first device on the market to receive FDA Clearance as a medical device to treat hair loss (androgenetic alopecia) and stimulate hair growth. HairMax Laser devices have been the subject of 7 clinical studies proving both efficacy and safety with an over 90% success rate. Study results have been published in 6 peer-reviewed medical journals. HairMax Laser devices have been granted 8 FDA Clearances and hold 14 medical device licenses world-wide.

HairMax Welcomes Mary Brunetti as Brand Ambassador to Provide Expert Guidance on Styling and Managing Multiple Causes of Thinning Hair Including Covid-19 Hair Loss

Source

Recent Posts

Global Hair Care Products Market

Global Hair Care Products Market

/in /by

Global Hair Care Products Market

Market Scenario

Haircare products are used to maintain hygiene and treat hair-related issues. The main function of hair care products is to clean the dirt, dandruff, and oil from the hair and scalp, treat damaged hair, and maintain the moisture content. Generally, hair care products are produced by combining a surfactant, such as sodium lauryl sulfate or sodium Laureth sulfate, with a co-surfactant such as Cocamidopropyl betaine in water.

Speciality hair care products are also available in the market for various hair-related concerns such as dandruff, colour-treated hair, hair fall, split ends, and dry, damaged hair.

Prominent players in the market are focusing on product innovation by offering more innovative products to consumers to cater to different hair-related concerns.

Therefore, the global Hair Care Products Market is expected to witness high growth during the forecast period.

Segmentation

The global hair care products market has been segmented based on type, distribution channel, and region.

By type, the global hair care products market has been classified as shampoo, conditioner, hair oil, and others. The shampoo segment is expected to hold the majority market share and register the highest CAGR during the review period.

The global hair care products market has also been divided, on the basis of the distribution channel, into store-based and non-store-based. The store-based segment is further segmented into supermarkets and hypermarkets, convenience stores, and others. The store-based segment is expected to account for the larger revenue share of the market. However, the non-store-based segment is expected to exhibit a high growth rate during the forecast period, 2019 to 2024.

The global hair care products market has been segmented into four key regions, namely, North America, Europe, Asia-Pacific, and the rest of the world.

The hair care products market in North America has further been segmented into the US, Canada, and Mexico. The hair care products market in Europe has been classified into the UK, Germany, France, Italy, Spain, and the rest of Europe. The hair care products market in Asia-Pacific has been segmented into China, India, Japan, Australia and New Zealand, and the rest of Asia-Pacific. The hair care products market in the rest of the world has been segmented into South America, the Middle East, and Africa.

Key Players

Unilever PLC (UK), Henkel AG & Company, KGaA (Germany), The Procter & Gamble Company (US), Church & Dwight Co., Inc. (US), Kimberly-Clark Corporation (US), Kao Corporation (Japan), Beiersdorf AG (Germany), Shiseido Company, Limited (Japan), L’Oréal S.A. (France), Vogue International LLC (US), Natura (Brazil) International B.V. (Brazil), BBLUNT (India), VLCC Healthcare Limited (India), Forest Essentials (India) and Johnson & Johnson Services, Inc (US) are some of the key players operating in the global hair care products market.

Regional Market Summary

Global Hair Care Products Market Share (%), by Region, 2018

Asia-Pacific is expected to dominate the global hair care products market during the forecast period due to the growing hair-related concerns and the growing demand for innovative products. This enables brands to launch products according to the requirement of the consumers. The market in North America is projected to register the highest growth rate during the forecast period owing to the high per capita disposable incomes and increasing consumer spending on new and innovative hair care products in the region.

Global Hair Care Products Market, by Type

  • Shampoo
  • Conditioner
  • Hair Oil
  • Others

Global Hair Care Products Market, by Distribution Channel

  • Store-Based
    • Supermarkets and Hypermarkets
    • Convenience Stores
    • Others
  • Non-Store-Based

Global Hair Care Products Market, by Region

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia and New Zealand
    • Rest of Asia-Pacific
  • Rest of the World (RoW)
    • South America
    • Middle East
    • Africa

Intended Audience

  • Personal care product manufacturers
  • Cosmetics manufacturers
  • Personal care retail outlets
  • Raw material suppliers and distributors
  • Traders, exporters, and importers

Global Hair Care Products Market

Source

Recent Posts

Preclinical Study of Hair Loss Therapeutic Candidate

Preclinical Study of Hair Loss Therapeutic Candidate

/in /by

OliX Pharmaceuticals Announces Results from Preclinical Study of Hair Loss Therapeutic Candidate

OliX Pharmaceuticals, Inc, a leading developer of RNAi therapeutics, announced that it has demonstrated efficacy in a preclinical study of OLX104C, an investigational RNAi therapeutic in development for androgenic alopecia, also known as hair loss.

In the study, OLX104C was administered topically to a mouse model with suppressed hair growth (Dihydrotestosterone, DHT administered mouse). The study evaluated the percentage of hair regrowth and duration of knockdown of the target protein, AR, following a single injection.

Mice receiving OLX104C showed substantial hair regrowth compared to the control group, and results showed that a single dose could inhibit the expression of the target gene for more than three weeks.

“We are advancing a novel and potentially durable approach to treating hair loss with large market potential,” said Dong Ki Lee, PhD, founder and chief executive officer of OliX Pharmaceuticals. “Due to topical administration, our investigational therapy acts directly on the affected area and is rapidly degraded upon exposure to the blood, so it’s free from major systemic side effects such as sexual dysfunction caused by conventional hair loss therapeutics.

Building on our experience evaluating RNAi therapeutics for skin diseases, we plan to initiate clinical trials of OLX104C by 2022.”

According to Inkwood Research, the global hair loss treatment market size is estimated to grow 5.51% annually from $8.4 billion in 2018 to $13.6 billion in 2027.1

Furthermore, OliX has completed patent applications in major global markets, including the United States, Europe, Korea, and Japan, to secure exclusive rights for its hair loss treatment substance.

Dr Lee will discuss the preclinical results of OLX104C and present a corporate overview at SMi’s 12th Annual RNA Therapeutics Virtual Conference on February 11, 2021, at 9:40 a.m. GMT.

About OliX Pharmaceuticals

OliX Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes, based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered as the most efficient gene silencing technology.

Based on asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target locally administrable diseases, such as hypertrophic scar, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, idiopathic pulmonary fibrosis (IPF), and neuropathic pain.

OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

To learn more about the company, visit https://www.olixpharma.com/eng/

1 Inkwood Research. Global Alopecia (Hair Loss) Treatment Market Forecast 2019-2027. Available at: https://www.inkwoodresearch.com/reports/global-alopecia-hair-loss-treatment-market/. Accessed February 9, 2021.

OliX Pharmaceuticals Announces Results from Preclinical Study of Hair Loss Therapeutic Candidate

Source

Recent Posts

Ziering Medical Center Opens in Greenwich, CT

Ziering Medical Center Opens in Greenwich CT

/in /by

Ziering Medical Center Opens in Greenwich, CT – Dr Rae Lynne Kinler Heads Up Leading Hair Restoration Clinic

Dr Craig Ziering announces the opening of his newest clinic in Greenwich, Connecticut with the lead surgeon, Rae Lynne Kinler, M.D. Dr Ziering will serve as Medical Director for the location, the fifth in the group.

Dr Kinler, the first physician in her family, is one of the few female hair transplant specialists in the field and a top tier aesthetic surgeon specializing in a range of hair restoration techniques and treatments. Having successfully completed a year-long fellowship in Hair Restoration Surgery with Dr Ziering, she was his top pick to join the highly respected Ziering Medical team in the fall of 2015 as a full-time hair transplant surgeon in Los Angeles. She has participated in research and development of Restoration Robotics with Dr Ziering and has been invited to lecture on the topic at industry conferences.

According to Dr Ziering, “I am so proud to have Dr Kinler introduce the Ziering brand of treatments to the greater Greenwich community. Our advanced protocols and her exceptional surgical skills will elevate the category of hair restoration to local residents.”

Dr Ziering is a pioneer in hair transplantation leadership, technology and education, who established his renowned Ziering Medical Group and brand in 2003 offering highly sought after surgical procedures, non-invasive hair loss treatments, advanced technologies, home care treatments, topicals and supplements.

“Greenwich was the ideal community for the next phase of our expansion,” said Anthony Castore, CEO of Ziering Medical. “This second east coast location gives us a broader-base to serve our clientele locally with integrated treatment and regular ongoing follow-up as we continue to grow the Ziering brand on a national scale.”

Ziering Medical currently serves a discerning global patient population, including high-profile personalities and public figures.

According to Dr Kinler, “To be the best you have to be trained by the best and the experience with Dr Ziering enabled me to be highly proficient in the latest in all surgical hair restoration procedures for men and women like Microscopically Dissected Elliptical Excision (MDEE) and particularly Follicular Unit Excision and Extraction (FUE).” A marathoner happy to be on the East Coast where she will continue to compete in IRONMAN and the NYC Marathon, she added, “I want to eliminate the stigma from hair restoration and hair transplantation procedures, especially for those with genetic predispositions. We can intervene early, manage the condition and ensure the best, the most natural outcome for permanent, undetectable results for our patients.”

Dr Kinler and her team are situated in their new office consisting of three state-of-the-art exam and surgical rooms in 2513 square feet of space located at 75 Holly Hill Lane, Suite 302, Greenwich, Connecticut 06830. Fully Covid-19 compliant, Ziering Medical of Greenwich is taking individual patients with clearance following all CDC protocols and provisions to keep patients and staffing safe and healthy.

Ziering Medical Greenwich will offer all their signature services for male and female hair loss, including hairline restoration, beard and eyebrow hair transplants, truly customized hair restoration treatment plans for men, women transgender and African American patients, as well as minimally-invasive office treatments. Dr Kinler is available for both virtual and in-person consultations. Additionally, she is available for public speaking engagements for local organizations. For more information visit Ziering Medical.

About Ziering Medical:

Founded in 2003 by Dr Craig Ziering, a global leader in hair restoration, Ziering Medical is a multi-dimensional and fully comprehensive hair restoration practice combining state-of-the-art hair transplant procedures and hair regeneration therapies with highly personalized treatment programs to manage the progressive nature of hair loss. Dr Ziering serves as Medical Director to four locations in Beverly Hills and Newport Beach, CA, Las Vegas, NV, Greenwich, CT, and a newly renovated flagship surgery centre in New York City.

Ziering Medical offers services for male and female pattern baldness as well as expertise in African American hair, transgender hairline modification, beard and eyebrow restoration, using many techniques pioneered by Dr Ziering. Understanding each patient’s unique hair restoration journey, Microscopically Dissected Elliptical Excision (MDEE) and Follicular Unit Excision and Extraction (FUE) are performed by Ziering surgeons, allowing for truly customized, personal treatment plans.

Taking a distinctive lifestyle approach, Ziering Medical provides a full array of non-surgical treatments and at-home care, including the Ziering Laser Cap, ZMin and ZFin, specially formulated topical minoxidil and finasteride, respectively. Stem cell scalp injection treatments with Amnio Z and Exosomes and lasers are all designed to meet the long term strategies and patient population needs.

The first branded product line, a speciality hair loss shampoo and conditioner, formulated by Dr Ziering, called Follicle Cleanse and Follicle Sustenance, will be available in early 2021.

Ziering Medical Center Opens in Greenwich, CT – Dr Rae Lynne Kinler Heads Up Leading Hair Restoration Clinic

Source

Recent Posts

Hair Loss Treatment Industry Market

Hair Loss Industry Market

/in /by

COVID-19 Outbreak-Global Hair Loss Medication Industry Market Report

The Hair Loss Medication market revenue was xx.xx Million USD in 2019 and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025.

Under COVID-19 outbreak globally, this report provides 360 degrees of analysis from the supply chain, import and export control to regional government policy and future influence on the industry. Detailed analysis about market status (2015-2020), enterprise competition pattern, advantages and disadvantages of enterprise Products, industry development trends (2020-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included.

From raw materials to end-users of this industry are analyzed scientifically, the trends of product circulation and sales channel will be presented as well. Considering COVID-19, this report provides comprehensive and in-depth analysis of how the epidemic pushes this industry transformation and reform.

In COVID-19 outbreak, Chapter 2.2 of this report provides an analysis of the impact of COVID-19 on the global economy and the Hair Loss Medication industry.

Chapter 3.7 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.

In addition, chapters 7-11 consider the impact of COVID-19 on the regional economy.

The Hair Loss Medication market can be split based on product types, major applications, and important countries as follows:

Key players in the global Hair Loss Medication market covered in Chapter 12:

Johnson & Johnson
Kirkland Signature
Gerolymatos International
Merck
Nanogen
Phyto Ales Group
Keranique
Amplixin
DS Healthcare Group
Ultrax Labs
Pharma Medico
Bayer
Oxford BioLabs

In Chapter 4 and 14.1, on the basis of types, the Hair Loss Medication market from 2015 to 2025 is primarily split into:

Androgenic Alopecia
Alopecia Areata
Ciatricial Alopecia
Traction Alopecia
Alopecia Totalis

In Chapter 5 and 14.2, on the basis of applications, the Hair Loss Medication market from 2015 to 2025 covers:

Hospitals
Retail Pharmacies
Online Pharmacies

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 6, 7, 8, 9, 10, 11, 14:

North America (Covered in Chapter 7 and 14)

United States

Canada

Mexico

Europe (Covered in Chapter 8 and 14)

Germany

UK

France

Italy

Spain

Russia

Others

Asia-Pacific (Covered in Chapter 9 and 14)

China

Japan

South Korea

Australia

India

Southeast Asia

Others

Middle East and Africa (Covered in Chapter 10 and 14)

Saudi Arabia

UAE

Egypt

Nigeria

South Africa

Others

South America (Covered in Chapter 11 and 14)

Brazil

Argentina

Columbia

Chile

Others

Years considered for this report:

Historical Years: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2020-2025

COVID-19 Outbreak-Global Hair Loss Medication Industry Market Report

Source

Recent Posts

Follica Announces Positive Topline Data from Clinical Study in Male Androgenetic Alopecia

Follica Announces Pilot Study for Female Pattern Hair Loss

/in /by

Follica Announces Pilot Study for Female Pattern Hair Loss Published in International Journal of Women’s Dermatology

Follica, a biotechnology company developing a regenerative platform designed to treat androgenetic alopecia, epithelial ageing and other related conditions, today announced the publication of a pilot study evaluating scalp skin disruption to promote hair growth in female pattern hair loss (FPHL) in International Journal of Women’s Dermatology.

The treatment promoted hair growth over a four-month course of treatment.

The pilot study, led by Maryanne M. Senna, M.D., an assistant professor of dermatology at Harvard Medical School, enrolled 11 women with mild to moderate FPHL who had been on stable existing treatments for six or more months.

Patients underwent six treatments with the Follica proprietary Hair Follicle Neogenesis (HFN) device and application of a topical on-market drug on non-treatment days.

The scalp treatments with the HFN device, which last just a few minutes, stimulate stem cells and enable the growth of new hair follicles. A topical drug is then applied to enhance efficacy by thickening new hair follicles and hair on the scalp. The study endpoints included photographs, physician-documented Sinclair score and patient-reported improvement.

At the end of the study, 10 out of the 11 patients reported perceived improvement in hair growth and all 11 improved on their physician-graded Sinclair scores. Average improvement on the Sinclair scale, which runs from stage 1 to stage 5, was one full stage. The adverse events reported were mild and self-resolving, and all women completed the course of treatment. Although the sample size was limited, the study’s authors called the results encouraging and called for larger studies.

“Around 40 per cent of women show signs of hair loss by age 50, and for many, this starts at an earlier age. Although many women struggle with this condition, there are very few effective treatment options available, and all too often, investigational therapies are tested primarily in men,” said Dr Senna, who directs the hair loss clinic at Massachusetts General Hospital.

“This pilot study was small but encouraging, as almost all of the patients reported meaningful improvements. This was especially welcome since many of these women had tried other treatments without success. There’s a significant treatment gap for women in this field, and it’s terrific to see new approaches with the potential to close that gap. I look forward to additional research on how the Follica device could address female pattern hair loss.”

“This study demonstrates the potential of our regenerative approach at Follica, which is intended to create an embryonic window in adult skin, essentially allowing new follicles and new hair to form from epithelial stem cells. It confirms that, while our treatment may not yet be optimized for females, the mechanism of action has the potential to address both male and female androgenetic alopecia and makes clear that the device works well with longer hair as well as shorter hair,” said Jason Bhardwaj, CEO of Follica. “We’re excited to continue advancing our technology as we work to bring effective new treatment options to both men and women.”

Follica plans to advance its lead program into Phase 3 development in 2021, following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia and a successful meeting with the Food and Drug Administration at the conclusion of the Phase 2 study.

The optimization study in male androgenetic alopecia was designed to select the optimal treatment regimen using Follica’s proprietary device in combination with a topical drug and successfully met its primary endpoint. The selected treatment regimen demonstrated a statistically significant 44 per cent improvement of non-vellus (visible) hair count after three months of treatment compared to baseline (p < 0.001, n = 19).

About Follica

Follica is a biotechnology company developing a regenerative platform designed to treat androgenetic alopecia, epithelial ageing and other related conditions. Founded by PureTech (LSE: PRTC, Nasdaq: PRTC), a co-inventor of the current platform and a group of world-renowned experts in hair follicle biology and regenerative medicine, Follica’s experimental treatment platform is designed to induce an embryonic window via a device with optimized parameters to initiate hair follicle neogenesis, the formation of new hair follicles from epithelial (skin) stem cells.

This process is enhanced through the application of a topical compound. Follica completed a safety and efficacy optimization study in 2019, and its Phase 3 registration program in male androgenetic alopecia is expected to begin in 2021. Follica’s technology is based on work originating from the University of Pennsylvania that has been further developed by Follica’s internal program. Follica’s extensive IP portfolio includes IP exclusively licensed from the University of Pennsylvania as well as Follica-owned IP.

Follica Announces Pilot Study for Female Pattern Hair Loss Published in International Journal of Women’s Dermatology

Source

Recent Posts

LICHEN Professional

LICHEN Professional

/in /by

Hair experts LICHEN Professional chose Cosmoprof Asia Digital Week to introduce their home-use products to the world

At Cosmoprof Asia Digital Week, the first ever digital edition of the region’s most renowned annual cosmetics and beauty event, LICHEN Professional responded to the current trend of home-use products with their hair colour and anti-hair loss products.

Super fast colour

With hairdressers currently unable to operate in some parts of the world, Lichen’s hair colour shampoo is the ideal stand in for those with black or brown hair. So easy to apply at home, it takes only five minutes to cover the hair with a colour that will last up to four weeks. As well as colouring the hair, the shampoo strengthens and nourishes each and every strand, as well as the roots. Once rinsed and dried, the hair looks shiny, feels silky and, just as importantly, boosts inner confidence once again.

Hair repair for anti-hair loss

Lichen’s Anti-Hair Loss Treatment is a combination of shampoo, conditioner, hair mask and hair oil. The 4-in-1 product makes it easy for anyone to stop having to worry about hair loss. Starting with a deep repair to the damaged hair, the product works to increase the health of the entire hair thanks to active precious plant essences as well as ingredients such as vitamin E, collagen and vitamin B5. The hair finish is nourished and moisturised on the inside and smooth, soft and bright on the outside.

About LICHEN Professional

Founded in 2010, Guangzhou LICHEN Cosmetic Co., Ltd is headquartered near the southern Chinese city’s airport. Focused on providing OEM hair care, LICHEN offers hair colour shampoo, as well as shampoo, conditioner, styling and treatment products. The company also works with clients on customised formulas for various requirements.

Comprising an FDA and ISO certified factory of 12,000 square meters, the company’s manufacturing space includes nine automatic process lines and a 400-square-meter lab, dedicated to ensuring the products that leave the factory are of the highest standard. The fast production line can handle minimum order quantities of testing trial orders as well as large-scale requests.

Lichen follows international standards throughout the process, and exports products to about 50 countries’ supermarkets, pharmacies, salons and stylists as well as to online stores. The company prides itself on its guarantee of quality, professional sales and after-sales services, and a team that creates these products with passion, efficiency and conscientiousness.

For product enquiry, please contact Anne Tang at 86-13538739819 or send an email to sales@lichenhaircolor.com.

About Cosmoprof Asia Digital Week

The first-ever edition of Cosmoprof Asia Digital Week has concluded successfully, creating copious business opportunities for the world’s companies and operators looking for new business solutions in the Asia-Pacific region.

652 exhibitors from 19 countries and regions took part in the event. 8,953 visitors from 115 countries and regions registered on the platform in order to virtually network, learn about current and upcoming trends. Cosmoprof Asia Digital Week offered a vital virtual business arena for the whole beauty industry while we are all waiting to meet again in Hong Kong in November 2021 for Cosmoprof Asia. Stay tuned for updates.

Hair experts LICHEN Professional chose Cosmoprof Asia Digital Week to introduce their home-use products to the world

Source

Recent Posts